World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
141
Citations
131989
World Ranking
1582
National Ranking
925

Dennis J. Slamon publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Dennis J. Slamon sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 537 publications — 64th percentile

64% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Dennis J. Slamon D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Dennis J. Slamon sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 141 D-Index — 92nd percentile

92% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2007 - Canada Gairdner International Award
  • 2006 - Warren Alpert Foundation Prize For their contribution to the development of the breast cancer therapy Herceptin, the first target-directed cancer treatment for solid tumors.

Overview

Dennis J. Slamon is affiliated with the University of California, Los Angeles in the United States. Their research spans multiple areas within medicine, particularly focusing on oncology and molecular biology with significant contributions in breast cancer treatment. The scientist's main fields of study include Medicine and Biochemistry, Genetics and Molecular Biology. Their subfields of focus are Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology, and Genetics.

The research topics associated with Dennis J. Slamon concentrate on:

  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Breast Cancer Treatment Studies
  • Cancer-related Molecular Pathways
  • Cancer Treatment and Pharmacology
  • Lung Cancer Research Studies
  • Cancer Genomics and Diagnostics

The scientist has published extensively in several academic journals, frequently contributing to:

  • Cancer Research
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Clinical Cancer Research
  • bioRxiv (Cold Spring Harbor Laboratory)

Among their recent publications are:

  • Ribociclib plus Endocrine Therapy in Early Breast Cancer, 2024, New England Journal of Medicine
  • Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival, 2021, Annals of Oncology
  • Cycling cancer persister cells arise from lineages with distinct programs, 2021, Nature
  • Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials, 2021, The Lancet Oncology

Frequent co-authors collaborating with Dennis J. Slamon include:

  • Sara A. Hurvitz
  • Neil A. O'Brien
  • Martina S.J. McDermott
  • Michael F. Press
  • Sherene Loi

The scientist's work has been recognized with the following awards:

  • Canada Gairdner International Award, 2007
  • Warren Alpert Foundation Prize, 2006, for contribution to the development of the breast cancer therapy Herceptin, the first target-directed cancer treatment for solid tumors

Best Publications

  • Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

    Dennis J. Slamon;Gary M. Clark;Steven G. Wong;Wendy J. Levin

  • Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

    Dennis J. Slamon;Brian Leyland-Jones;Steven Shak;Hank Fuchs

  • Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

    Dennis J. Slamon;William Godolphin;Lovell A. Jones;John A. Holt

  • Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

    Charles L. Vogel;Melody A. Cobleigh;Debu Tripathy;John C. Gutheil

  • Adjuvant trastuzumab in HER2-positive breast cancer.

    Dennis Slamon;Wolfgang Eiermann;Nicholas Robert;Tadeusz Pienkowski

  • Palbociclib and Letrozole in Advanced Breast Cancer

    Richard S. Finn;Miguel Martin;Hope S. Rugo;Stephen Jones

  • Expression of a multidrug-resistance gene in human tumors and tissues

    A T Fojo;K Ueda;D J Slamon;D G Poplack

  • Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

    Katherine B. Chiappinelli;Pamela L. Strissel;Alexis Desrichard;Huili Li

  • Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

    Massimo Cristofanilli;Nicholas C. Turner;Igor Bondarenko;Jungsil Ro

  • Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

    Mark D. Pegram;Allen Lipton;Daniel F. Hayes;Barbara L. Weber

  • A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers

    James R. Bischoff;Lee Anderson;Yingfang Zhu;Kevin Mossie

  • The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

    Richard S Finn;John P Crown;Istvan Lang;Katalin Boer

  • Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma

    Siân Jones;Tian Li Wang;Ie Ming Shih;Tsui Lien Mao

  • PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

    Richard S Finn;Judy Dering;Dylan Conklin;Ondrej Kalous

  • Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells

    Gottfried E. Konecny;Mark D. Pegram;Natarajan Venkatesan;Richard Finn

  • Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

    Rashmi K Murthy;Sherene Loi;Alicia Okines;Elisavet Paplomata

  • Expression of cellular oncogenes in human malignancies

    Dennis J. Slamon;Jean B. deKernion;Inder M. Verma;Martin J. Cline

  • Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

    Nicholas C Turner;Dennis J Slamon;Jungsil Ro;Igor Bondarenko

  • Assessment of Methods for Tissue-Based Detection of the HER-2/neu Alteration in Human Breast Cancer: A Direct Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry

    Giovanni Pauletti;Suganda Dandekar;HongMei Rong;Lilllian Ramos

  • HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

    Michael F. Press;Leslie Bernstein;Patricia A. Thomas;Lorraine F. Meisner

Frequent Co-Authors

Michael F. Press
Michael F. Press University of Southern California
Richard S. Finn
Richard S. Finn University of California, Los Angeles
Sara A. Hurvitz
Sara A. Hurvitz Fred Hutchinson Cancer Research Center
Beth Y. Karlan
Beth Y. Karlan University of California, Los Angeles
John Crown
John Crown Dublin City University
He-Jing Wang
He-Jing Wang University of California, Los Angeles
Marc Buyse
Marc Buyse Hasselt University
Karen A. Gelmon
Karen A. Gelmon University of British Columbia
Matthias W. Beckmann
Matthias W. Beckmann University of Erlangen-Nuremberg
Joan S. Brugge
Joan S. Brugge Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The healthcare landscape in the USA is changing rapidly, and online degrees are an increasingly popular way to advance or pivot within the field of medicine. For those seeking advanced practice or academic roles, online nursing doctoral programs offer flexibility and affordability, making a terminal degree more accessible for working nurses.

Looking to build on your current credentials? Explore the cheapest rn to bsn online programs, which are designed for registered nurses wanting to expand their career options with a bachelor’s degree. These cost-effective pathways can be completed while balancing work or family commitments.

If you hold a non-nursing bachelor’s degree but want to enter the nursing profession, consider direct entry msn programs for non-nursing majors online. These programs offer accelerated routes to become a registered nurse and earn a master’s degree, even with no prior nursing experience.

For those beginning their nursing journey, adn programs represent a flexible and accessible starting point. This pathway is ideal for those who want to quickly enter the workforce while keeping future advancement options open.

Best Scientists Citing Dennis J. Slamon

Trending Scientists